KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Work In Process (2018 - 2021)

Historic Work In Process for BioNTech SE (BNTX) over the last 4 years, with Q4 2021 value amounting to $96.7 million.

  • BioNTech SE's Work In Process rose 31791.52% to $96.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $96.7 million, marking a year-over-year increase of 31791.52%. This contributed to the annual value of $96.7 million for FY2021, which is 31791.52% up from last year.
  • BioNTech SE's Work In Process amounted to $96.7 million in Q4 2021, which was up 31791.52% from $67.2 million recorded in Q2 2021.
  • BioNTech SE's Work In Process' 5-year high stood at $96.7 million during Q4 2021, with a 5-year trough of $91311.7 in Q4 2018.
  • Its 4-year average for Work In Process is $38.1 million, with a median of $23.1 million in 2020.
  • In the last 5 years, BioNTech SE's Work In Process soared by 340085.6% in 2019 and then skyrocketed by 31791.52% in 2021.
  • Over the past 4 years, BioNTech SE's Work In Process (Quarter) stood at $91311.7 in 2018, then surged by 3400.86% to $3.2 million in 2019, then surged by 623.57% to $23.1 million in 2020, then surged by 317.92% to $96.7 million in 2021.
  • Its last three reported values are $96.7 million in Q4 2021, $67.2 million for Q2 2021, and $23.1 million during Q4 2020.